Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 4/20 | 0.45 |
| ▸ | EDNRA | P25101 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310277 | 0.83 | CA1 (0.49) | EDNRBEDNRAKMT2AGLASMN1; SMN2 | |
| SCHEMBL30200885 | 0.83 | CA1 (0.49) | EDNRBEDNRAKMT2AGLASMN1; SMN2 | |
| SCHEMBL4616375 | 0.82 | LMNA (0.45) | KMT2ASMN1; SMN2IDH1LMNACA2 | |
| SCHEMBL265203 | 0.81 | EDNRB (0.46) | EDNRBEDNRAKMT2AGLASMN1; SMN2 | |
| SCHEMBL9196907 | 0.81 | EDNRB (0.46) | EDNRBEDNRAKMT2AGLASMN1; SMN2 | |
| SCHEMBL6465 | 0.79 | EDNRB (0.45) | EDNRBEDNRAKMT2AGLASMN1; SMN2 | |
| SCHEMBL1346608 | 0.79 | CA2 (0.49) | EDNRBEDNRAKMT2ALMNACA1 | |
| SCHEMBL742725 | 0.78 | KMT2A (0.49) | EDNRBEDNRAKMT2ASMN1; SMN2LMNA | |
| SCHEMBL197054 | 0.78 | S100A4 (0.48) | GLASMN1; SMN2LMNACA1CA2 | |
| SCHEMBL198775 | 0.78 | LMNA (0.44) | EDNRBEDNRAKMT2AGLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4644375-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-11-05 | — | — | EP | disclosed |
| EP-4580621-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | The Broad Institute, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025136671-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | Ensem Therapeutics (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240228481-A1 | NOVEL SULFONAMIDE SERIES OF QR2 INHIBITORS TO TACKLE OXIDATIVE STRESS AND COGNITIVE DECLINE | CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2024-07-11 | — | — | US | disclosed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| US-5473067-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| US-5424448-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0617038-A1 | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5344929-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-4804673-A | Fungicidal sulfonyl azoles | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-02-14 | — | — | US | disclosed |
| US-4710509-A | IMIDAZOLE AND TRIAZOLE DERIVATIVES; FUNGICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1987-12-01 | — | — | US | disclosed |
| EP-0237912-A1 | Sulfonyl azoles | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1987-09-23 | — | — | EP | disclosed |
| US-4222937-A | Total synthesis of the utero-evacuant substance D,L-zoapatanol | ORTHO PHARMACEUTICAL CORP. (US) | 1980-09-16 | — | — | US | disclosed |
| US-4177194-A | Total synthesis of the utero-evacuant substance D,L-zoapatanol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
| US-3943157-A | Synthesis of codling moth attractant | ZOECON CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | EDNRB 947/4885EDNRA 1060/4885KMT2A 1435/4885 |
| US-20240228481-A1 | NOVEL SULFONAMIDE SERIES OF QR2 INHIBITORS TO TACKLE OXIDATIVE STRESS AND COGNITIVE DECLINE | SQOR, NFE2L2, TXNRD2 | EDNRB 1636/4885EDNRA 1461/4885KMT2A 354/4885 |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | CDK2, CDK3, CDK4 | EDNRB 4042/4885EDNRA 4297/4885KMT2A 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.